Phase II Clinical Study for Patients with IPF

  • Date October 2020
  • Therapeutic Area Idiopathic Pulmonary Fibrosis
  • Challenges Covid-19 pandemic | Rare disease | High patient burden (1 year-long commitment)

Responsum was brought in to boost enrollment in the US market quickly. This was the first time Responsum supported a clinical trial campaign.

Strategy:

Leveraging our 3.6K+ member pulmonary fibrosis community, we launched a targeted campaign centered on clinical trial education, streamlined phone screening, and a personalized email drip campaign designed to align with participants’ preferences and demographics.

52 patients were referred successfully, 13 screened, and 8 randomized. All from our IPF community.

    Testimonials and reviews from our customers

    What our customers are saying about us